产品
编 号：F756295
分子式：C26H25FN2O4S
分子量：480.55
分子式：C26H25FN2O4S
分子量：480.55
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2839471-44-0
产品详情
生物活性：
LPA5 antagonist 2 (compound 65) is a high aqueous solubility LPA5 (lysophosphatidic acid receptor 5) antagonist. LPA5 antagonist 2 significantly attenuates nociceptive hypersensitivity and it can be used for the research of inflammatory and neuropathic pains.
体内研究：
LPA5 antagonist 2 (5.3-17.8 mg/kg; i.p. once) alleviates CFA-induced inflammatory pain in vivo.Animal Model:Adult male Sprague-Dawley rats with CFA-induced pain
Dosage:5.6, 10 and 17.8 mg/kg
Administration:Intraperitoneal injection; 5.6, 10 and 17.8 mg/kg once
Result:Markedly alleviated nociceptive hypersensitivity and showed about five hours lasting time.
体外研究：
LPA5 antagonist 2 (0-10 μM) inhibits hLPA5 calcium mobilization with an IC50 value of 69 nM and inhibits hLPA5 cAMP with an IC50 value of 340 nM.LPA5 antagonist 2 (0-10 μM) shows no significant affinity for other receptors, exhibits good target selectivity for LPA5.
LPA5 antagonist 2 (compound 65) is a high aqueous solubility LPA5 (lysophosphatidic acid receptor 5) antagonist. LPA5 antagonist 2 significantly attenuates nociceptive hypersensitivity and it can be used for the research of inflammatory and neuropathic pains.
体内研究：
LPA5 antagonist 2 (5.3-17.8 mg/kg; i.p. once) alleviates CFA-induced inflammatory pain in vivo.Animal Model:Adult male Sprague-Dawley rats with CFA-induced pain
Dosage:5.6, 10 and 17.8 mg/kg
Administration:Intraperitoneal injection; 5.6, 10 and 17.8 mg/kg once
Result:Markedly alleviated nociceptive hypersensitivity and showed about five hours lasting time.
体外研究：
LPA5 antagonist 2 (0-10 μM) inhibits hLPA5 calcium mobilization with an IC50 value of 69 nM and inhibits hLPA5 cAMP with an IC50 value of 340 nM.LPA5 antagonist 2 (0-10 μM) shows no significant affinity for other receptors, exhibits good target selectivity for LPA5.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备